3400-09-7

Basic information

• Product Name: Dichloramine
• Synonyms: Dichloroamine: (Chlorimide)
• CAS NO: 3400-09-7
• Molecular Formula: Cl₂HN
• Molecular Weight: 85.92
• Mol File: 3400-09-7.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 115-117 °C(Press: 15 Torr)
• Appearance: /
• Density: 1.429g/cm³
• Refractive Index: 1.424
• PKA: -11.14±0.70(Predicted)
• CAS DataBase Reference: Dichloramine(CAS DataBase Reference)
• NIST Chemistry Reference: Dichloramine(3400-09-7)
• EPA Substance Registry System: Dichloramine(3400-09-7)

Safety Data

• RIDADR: 3093
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 3400-09-7(Hazardous Substances Data)

Usage

General Description

Dichloramine, also known as nitrogen dichloride, is a chemical compound formed when chlorine gas is dissolved in water containing ammonia. It is a strong oxidizing and chlorinating agent, and is commonly used for disinfection and water treatment. Dichloramine is a powerful irritant to the eyes, skin, and respiratory system, and exposure to high concentrations can cause irritation, coughing, and shortness of breath. In addition, it can react with organic matter to form potentially harmful disinfection byproducts. The use of dichloramine in water treatment must be carefully controlled to minimize potential health risks and environmental impact.

InChI:InChI=1/Cl2HN/c1-3-2/h3H

Upstream product

• 24270-55-1 ammonium sulfate 
• 7681-52-9 sodium hypochlorite 
• 10025-85-1 nitrogen trichloride 
• 7732-18-5 water 
• 14362-44-8 iodide 
• 12190-75-9 chloroamine 
• 7647-01-0 hydrogenchloride 
• 7601-90-3 perchloric acid 
• 14989-30-1 hypochloric acid 
• 7664-41-7 ammonia 
• 10405-27-3 difluoroamine 
• 7782-50-5 chlorine 
• 14265-45-3 sulfite^(2-) 

Downstream Products

• 78755-81-4 flumazenil 
• 7727-37-9 nitrogen 
• 74004-38-9 N^(1-)Cl₂ 
• 10025-85-1 nitrogen trichloride 
• 12190-75-9 chloroamine 
• 7553-56-2 iodine 
• 15181-48-3 chlorosulfate anion 
• 7726-95-6 bromine 
• 14989-30-1 hypochloric acid 
• 7647-01-0 hydrogenchloride 
• 132897-82-6 1-(2,6-dichloro-4-trifluoromethylphenyl)-5-amino-2-methylimidazole 
• 78771-13-8 ethyl 7-chloro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate 
• 150879-21-3 (+/-)-2,6-Dichloro-4-phenyl-4-ethynyl-3-methyl-3,4-dihydroquinazoline 
• 150879-22-4 (+/-)-2,6-Dichloro-4-phenyl-4-ethyl-3-methyl-3,4-dihydroquinazoline 

Relevant articles and documents

The mechanism of monochloramine disproportionation under acidic conditions

Monochloramine is a widely employed agent in water treatment technologies. However, its utilization has some drawbacks like the transformation of the active species into the undesired dichloramine. Although it is more pronounced in acidic solutions, the f

Method and apparatus for producing synergistic biocide

An apparatus and methods to produce synergistic mixtures (or combinations) of haloamines to control growth of microorganisms in aqueous systems are disclosed. The apparatus and methods to produce synergistic mixtures entails producing a batch quantity of a haloamine and converting part of the haloamine to a second haloamine species to form the synergistic mixture.

BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY

Described herein are D4 receptor-selective compounds of the general formula: STR1 wherein: A and B are independently selected, substituted or unsubstituted, unsaturated 5-or 6-membered, homo-or heterocyclic rings;X 1 is selected from O, S, SO, SO 2, CH. sub.2, C=O, CH--OH, CH--N(C 1-4 alkyl) 2, C= CHCl, and C=CHCN;X 2---is selected from N= , CH. sub.2--, CH= and C(O)--;n is 1 or 2; R 1 is selected from H and the α-carbon side chain of an amino acid;R 2 and R 3 are selected independently from H, OH,--NH 2,--C(O)NH 2 =O, =S,halo, cyano, C 1-9 alkyl, C 1-9 alkoxy, C 1-4 alkylS--, C 1-4 alkylSO--, C 1-4 alkylSO 2--, phenoxy, benzyloxy and piperonyloxy; andH* is in either the R-or the S-configuration,and acid addition salts, solvates and hydrates thereof.Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.